BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33266496)

  • 1. Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.
    Bazzichetto C; Luchini C; Conciatori F; Vaccaro V; Di Cello I; Mattiolo P; Falcone I; Ferretti G; Scarpa A; Cognetti F; Milella M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
    Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
    Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma.
    Luchini C; Pea A; Lionheart G; Mafficini A; Nottegar A; Veronese N; Chianchiano P; Brosens LA; Noë M; Offerhaus GJA; Yonescu R; Ning Y; Malleo G; Riva G; Piccoli P; Cataldo I; Capelli P; Zamboni G; Scarpa A; Wood LD
    J Pathol; 2017 Oct; 243(2):148-154. PubMed ID: 28722124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils.
    Schawkat K; Manning MA; Glickman JN; Mortele KJ
    Radiographics; 2020; 40(5):1219-1239. PubMed ID: 32678699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
    Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
    Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomics of pancreatic ductal adenocarcinoma.
    Pilarsky C; Grutzmann R
    Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing.
    Ma H; Song B; Guo S; Li G; Jin G
    Cancer Biomark; 2020; 27(3):389-397. PubMed ID: 31958074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas.
    Gkountakos A; Mafficini A; Lou E; Malleo G; Salvia R; Calicchia M; Silvestris N; Racila E; Amin K; Veronese N; Brunetti O; Antonini P; Ingravallo G; Mattiolo P; Saponaro C; Nappo F; Simbolo M; Bariani E; Lonardi S; Fassan M; Milella M; Lawlor RT; Scarpa A; Luchini C
    Hum Pathol; 2022 Oct; 128():124-133. PubMed ID: 35850360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
    Voutsadakis IA; Digklia A
    Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
    Kimura H; Klein AP; Hruban RH; Roberts NJ
    Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer subtypes: a roadmap for precision medicine.
    Torres C; Grippo PJ
    Ann Med; 2018 Jun; 50(4):277-287. PubMed ID: 29537309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant epithelial/exocrine tumors of the pancreas.
    Luchini C; Grillo F; Fassan M; Vanoli A; Capelli P; Paolino G; Ingravallo G; Renzulli G; Doglioni C; D'Amuri A; Mattiolo P; Pecori S; Parente P; Florena AM; Zamboni G; Scarpa A
    Pathologica; 2020 Sep; 112(3):210-226. PubMed ID: 33179623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
    Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
    Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
    Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Ductal Adenocarcinoma and Its Variants.
    Luchini C; Capelli P; Scarpa A
    Surg Pathol Clin; 2016 Dec; 9(4):547-560. PubMed ID: 27926359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.
    Zhang X; Mao T; Zhang B; Xu H; Cui J; Jiao F; Chen D; Wang Y; Hu J; Xia Q; Ge W; Li S; Yue M; Ma J; Yao J; Wang Y; Wang Y; Shentu D; Zhang X; Chen S; Bai Y; Wang Y; Zhang X; Liu Q; Sun Y; Fu D; Liu Y; Xiong L; Wang L
    EBioMedicine; 2022 Mar; 77():103897. PubMed ID: 35231699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organoid models for translational pancreatic cancer research.
    Tiriac H; Plenker D; Baker LA; Tuveson DA
    Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling.
    Yamamoto KN; Yachida S; Nakamura A; Niida A; Oshima M; De S; Rosati LM; Herman JM; Iacobuzio-Donahue CA; Haeno H
    Cancer Res; 2017 Jun; 77(12):3325-3335. PubMed ID: 28381541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.